BioSpace News Archive

Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

The Offering consisted of the issuance of an aggregate of 8,606,071 Units at a price of $0.14 per Unit.

Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that Marshall Fordyce, MD, founder and CEO, will present and participate in one-on-one investor meetings at the 42nd Annual Cowen Health Care Conference.

Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8th at 11:10 AM ET.

Masoud Toloue, President of Quanterix and Diagnostics, to Become CEO and Join Board of Directors.

Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today published new CNS (Central Nervous System) therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year.

Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company’s Board of Directors, effective immediately.

Talis Biomedical Corporation (“TLIS”), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report fourth quarter and full year 2021 financial and operational results on Tuesday, March 15, 2022, after market close.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco.

Humacyte, Inc. announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will represent Humacyte at the following investor conferences in March.